Nancy Elizabeth Davis
Residential Contractor at Martin Luther King Jr Blvd, Chapel Hill, NC
License number
North Carolina 17338
Renew Date
Jan 21, 2016
Category
General Contractor
Type
Residential
Address
Address
976 Martin Luther King Jr Blvd STE 200, Chapel Hill, NC 27514
Phone
(828) 387-6788
Professional information
Nancy Worth Davis, Chapel Hill NC - Lawyer
Address:
Rutland Products, Rock Wool, M H Detrick
117 Donegal Dr, Chapel Hill 27517
(919) 659-8311
117 Donegal Dr, Chapel Hill 27517
(919) 659-8311
Licenses:
South Carolina - Good Standing 1996
Education:
University of Miami School of LawGraduated 1981
Alphavirus Rna Replicon Systems
US Patent:
6531135, Mar 11, 2003
Filed:
Jun 21, 2000
Appl. No.:
09/598569
Inventors:
Robert E. Johnston - Chapel Hill NC
Nancy L. Davis - Chapel Hill NC
Jonathan F. Smith - Sabillasville MD
Peter Pushko - Frederick MD
Michael Parker - Frederick MD
George Ludwig - Frederick MD
Nancy L. Davis - Chapel Hill NC
Jonathan F. Smith - Sabillasville MD
Peter Pushko - Frederick MD
Michael Parker - Frederick MD
George Ludwig - Frederick MD
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 3912
US Classification:
4241991, 4242181, 4352351, 435236, 4353201
Abstract:
The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the alphavirus structural protein encoded by the first helper RNA, and (ii) encoding the at least alphavirus one structural protein not encoded by the first helper RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell. Preferably, the helper cell also includes a replicon RNA encoding an alphavirus packaging sequence and an inserted heterogeneous RNA.
Alphavirus Rna Replicon Systems
US Patent:
6541010, Apr 1, 2003
Filed:
Nov 10, 1997
Appl. No.:
08/981159
Inventors:
Robert E. Johnston - Chapel Hill NC
Nancy L. Davis - Chapel Hill NC
Jonathan F. Smith - Sabillasville MD
Peter Pushko - Frederick MD
Michael Parker - Frederick MD
George Ludwig - Frederick MD
Nancy L. Davis - Chapel Hill NC
Jonathan F. Smith - Sabillasville MD
Peter Pushko - Frederick MD
Michael Parker - Frederick MD
George Ludwig - Frederick MD
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 3912
US Classification:
4241991, 4242181, 424 932, 4352351, 435236, 435239, 435325
Abstract:
The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the alphavirus structural protein encoded by the first helper RNA, and (ii) encoding the at least one alphavirus structural protein not encoded by the first helper RNA. Preferably, the helper cell is co-transfected with a replicon RNA encoding an alphavirus packaging segment and an inserted heterogeneous RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell, with said replicon RNA packaged therein.
System For The In Vivo Delivery And Expression Of Heterologous Genes In The Bone Marrow
US Patent:
6583121, Jun 24, 2003
Filed:
Nov 12, 1999
Appl. No.:
09/367764
Inventors:
Robert E. Johnston - Chapel Hill NC
Nancy L. Davis - Chapel Hill NC
Dennis A. Simpson - Chapel Hill NC
Nancy L. Davis - Chapel Hill NC
Dennis A. Simpson - Chapel Hill NC
Assignee:
University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 4800
US Classification:
514 44, 4353201
Abstract:
The present invention provides a method of delivering immunogenic or therapeutic proteins to bone marrow cells using alphavirus vectors. The alphavirus vectors disclosed herein target specifically to bone marrow tissue, and viral genomes persist in bone marrow for at least three months post-infection. No or very low levels of virus were detected in quadricep, brain, and sera of treated animals. The sequence of a consensus Sindbis cDNA clone, pTR339, and infectious RNA transcripts, infectious virus particles, and pharmaceutical formulations derived therefrom are also disclosed. The sequence of the genomic RNA of the Girdwood S. A. virus, and cDNA clones, infectious RNA transcripts, infectious virus particles, and pharmaceutical formulations derived therefrom are also disclosed.
System For The In Vivo Delivery And Expression Of Heterologous Genes In The Bone Marrow
US Patent:
6008035, Dec 28, 1999
Filed:
Jun 22, 1998
Appl. No.:
9/102248
Inventors:
Robert E. Johnston - Chapel Hill NC
Nancy L. Davis - Chapel Hill NC
Dennis A. Simpson - Pittsboro NC
Nancy L. Davis - Chapel Hill NC
Dennis A. Simpson - Pittsboro NC
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
C12N 700, C12N 510, C12N 701, C12N 1511, C12N 1540
US Classification:
4352351
Abstract:
The present invention provides a method of delivering immunogenic or therapeutic proteins to bone marrow cells using alphavirus vectors. The alphavirus vectors disclosed herein target specifically to bone marrow tissue, and viral genomes persist in bone marrow for at least three months post-infection. No or very low levels of virus were detected in quadricep, brain, and sera of treated animals. The sequence of a consensus Sindbis cDNA clone, pTR339, and infectious RNA transcripts, infectious virus particles, and pharmaceutical formulations derived therefrom are also disclosed. The sequence of the genomic RNA of the Girdwood S. A. virus, and cDNA clones, infectious RNA transcripts, infectious virus particles, and pharmaceutical formulations derived therefrom are also disclosed.
System For The In Vivo Delivery And Expression Of Heterologous Genes In The Bone Marrow
US Patent:
5811407, Sep 22, 1998
Filed:
Feb 19, 1997
Appl. No.:
8/801263
Inventors:
Robert E. Johnston - Chapel Hill NC
Nancy L. Davis - Chapel Hill NC
Dennis A. Simpson - Pittsboro NC
Nancy L. Davis - Chapel Hill NC
Dennis A. Simpson - Pittsboro NC
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 4800, C12N 1564
US Classification:
514 44
Abstract:
The present invention provides a method of delivering immunogenic or therapeutic proteins to bone marrow cells using alphavirus vectors. The alphavirus vectors disclosed herein target specifically to bone marrow tissue, and viral genomes persist in bone marrow for at least three months post-infection. No or very low levels of virus were detected in quadricep, brain, and sera of treated animals. The sequence of a consensus Sindbis cDNA clone, pTR339, and infectious RNA transcripts, infectious virus particles, and pharmaceutical formulations derived therefrom are also disclosed. The sequence of the genomic RNA of the Girdwood S. A. virus, and cDNA clones, infectious RNA transcripts, infectious virus particles, and pharmaceutical formulations derived therefrom are also disclosed.
Method Of Inducing An Immune Response With A Live Venezuelan Equine Encephalitis Virus Expressing A Heterologous Immunogen
US Patent:
5643576, Jul 1, 1997
Filed:
May 19, 1995
Appl. No.:
8/444563
Inventors:
Robert E. Johnston - Chapel Hill NC
Nancy L. Davis - Chapel Hill NC
Jonathan F. Smith - Sabillasville MD
Franziska B. Grieder - Bethesda MD
Nancy L. Davis - Chapel Hill NC
Jonathan F. Smith - Sabillasville MD
Franziska B. Grieder - Bethesda MD
Assignee:
The University of North Carolina at Chapel Hill - Chapel Hill NC
International Classification:
A61K 3912, A61K 39193, C12N 704, C07H 2104
US Classification:
4241991
Abstract:
A method of protecting a subject against a disease comprises administering a recombinant Venezuelan Equine Encephalitis (VEE) virus to the subject in an effective immunogenic amount, with the VEE virus containing a heterologous DNA segment, and with the heterologous DNA segment comprising a promoter operable in the subject operatively associated with a DNA encoding an immunogenic protein or peptide effective for protecting the subject from the disease. Preferred promoters are VEE 26S subgenomic promoters, and preferred immunogens are viral immunogens. Novel attenuating mutations useful in carrying out the invention are also disclosed.
Alphavirus Rna Replicon Systems
US Patent:
5792462, Aug 11, 1998
Filed:
May 23, 1995
Appl. No.:
8/448630
Inventors:
Robert E. Johnston - Chapel Hill NC
Nancy L. Davis - Chapel Hill NC
Jonathan F. Smith - Sabillasville MD
Peter Pushko - Frederick MD
Michael Parker - Frederick MD
George Ludwig - Frederick MD
Nancy L. Davis - Chapel Hill NC
Jonathan F. Smith - Sabillasville MD
Peter Pushko - Frederick MD
Michael Parker - Frederick MD
George Ludwig - Frederick MD
Assignee:
University of North Carolina at Chapel Hill - Chapel Hill NC
The United States of America as represented by the Secretary of the Army - Washington DC
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 39295, C12N 510, C12N 701, C12N 1500
US Classification:
4241991
Abstract:
The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the alphavirus structural protein encoded by the first helper RNA, and (ii) encoding the at least alphavirus one structural protein not encoded by the first helper RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell. Preferably, the helper cell also includes a replicon RNA encoding an alphavirus packaging sequence and an inserted heterogeneous RNA.
Cdna Clone Coding For Venezuelan Equine Encephalitis Virus And Attenuating Mutations Thereof
US Patent:
5185440, Feb 9, 1993
Filed:
Jun 20, 1989
Appl. No.:
7/369023
Inventors:
Nancy L. Davis - Chapel Hill NC
Loretta V. Willis - Raleigh NC
Robert E. Johnston - Raleigh NC
Jonathan F. Smith - Frederick MD
Loretta V. Willis - Raleigh NC
Robert E. Johnston - Raleigh NC
Jonathan F. Smith - Frederick MD
Assignee:
North Carolina State University - Raleigh NC
International Classification:
C12N 1540, C12N 701, C12N 704, A61K 39193
US Classification:
5362372
Abstract:
A DNA comprises a cDNA clone coding for an infectious Venezuelan Equine Encephalitis Virus RNA transcript and a heterologous promoter sequence positioned upstream from the cDNA clone and operatively associated therewith. A method of making a live attenuated Togavirus useful as a vaccine, and cDNA clones which code for attenuated Togaviruses, is also disclosed.
Alphavirus Rna Replicon Systems
US Patent:
2004012, Jun 24, 2004
Filed:
Oct 10, 2003
Appl. No.:
10/683781
Inventors:
Robert Johnston - Chapel Hill NC, US
Nancy Davis - Chapel Hill NC, US
Jonathan Smith - Cary NC, US
Peter Pushko - Frederick MD, US
Michael Parker - Frederick MD, US
George Ludwig - Frederick MD, US
Nancy Davis - Chapel Hill NC, US
Jonathan Smith - Cary NC, US
Peter Pushko - Frederick MD, US
Michael Parker - Frederick MD, US
George Ludwig - Frederick MD, US
Assignee:
University of North Carolina at Chapel Hill
International Classification:
C12N015/86, C12N007/00
US Classification:
435/457000, 435/235100, 435/325000
Abstract:
The present invention provides a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the alphavirus structural protein encoded by the first helper RNA, and (ii) encoding the at least one alphavirus structural protein not encoded by the first helper RNA. Preferably, the helper cell is co-transfected with a replicon RNA encoding an alphavirus packaging segment and an inserted heterogeneous RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell, with said replicon RNA packaged therein.